Skip to main content
. 2017 Jul 26;7:6584. doi: 10.1038/s41598-017-06903-8

Figure 7.

Figure 7

A 68-year-old female breast cancer patient, pretreatment with 18F-FES PET/CT (A) showed high uptake in these metastatic lesions (SUVmax = 4.8–20.15). After two cycles of combination treatment (group TF), these lesions had obvious decreases in 18F-FES uptake (SUVmax = 2.31–7.26, B). The greatest change was observed in the right axillary lymph node (>70%, arrow). The patient had a PFS > 12 months.